Outsourcing-Pharma: FHI Clinical to support ACTT remdesivir trial for COVID-19

July 23, 2020
Claudia Christian, Senior Vice President, Clinical Operations at FHI Clinical, recently spoke with Jenni Spinner, editor for Outsourcing-Pharma, about the clinical services that FHI Clinical is providing to the Frederick National Laboratory for Cancer research (operated by Leidos Biomedical Research) for the ongoing Adaptive COVID-19 Treatment Trial (ACTT), an adaptive study allowing investigation of putative therapeutics for the treatment of COVID-19 in hospitalized adults. Claudia explained how FHI Clinical is a chosen partner because of existing solutions to support an emergency response:
Headhsots_600x600_72dpi_Claudia
CLAUDIA CHRISTIAN

Senior Vice President, Clinical Operations

“Specifically, during this outbreak, we have helped deploy a remote site selection and initiation training program. While our SMAs have carried out the majority of the site management activities, our field CRAs have joined in the virtual monitoring.”

Clinical services provided by FHI Clinical for the ACTT study include:
  • Site management
  • Meeting logistics
  • 24/7 call center
  • Trial master file management

news archive

Share this post

Share on linkedin
Share on twitter
Share on facebook